Roth Capital Pounds Table on Cytokinetics (CYTK) into AAN BENEFIT-ALS Presentation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Cytokinetics, Inc. (CYTK) to Present BENEFIT-ALS Results at 66th AAN
April 22, 2014 7:49 AM EDTCytokinetics, Incorporated (Nasdaq: CYTK) announced that results from BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS) will be presented during a Platform Session scheduled at the 66th Annual Meeting of the American Academy of Neurology (AAN) to be held April 26 - May 3, 2014 at the Pennsylvania Convention Center in Philadelphia, PA. Cytokinetics also announced that additional poster presentations related to tirasemtiv and ALS will be presented at AAN.
Platform Session Presentation at the 66th Annual Meeting of the American Academy of Neurology
Title: The Effect of Tirasemtiv on Functional... More
